Key result
Pharmacotherapy follow-up reduces depressive symptoms by a median 11 points over usual care.
Why the study?
Few studies using standardized methods such as randomized controlled trials have assessed the effectiveness of pharmacotherapy follow-up in patients with depression.
Does pharmaceutical care via pharmacotherapy follow-up improve depressive symptoms in female patients diagnosed with depression?
Comparison
Pharmacotherapy follow-up via Dáder Method vs usual treatment without pharmacotherapy follow-up
Design
Randomized controlled trial with stratified randomization
Follow-up
3 months
Loading...
PF via Dáder Method improves depressive and anxiety symptoms in women; extends pharmaceutical care evidence to depression and supports clinical integration.
RCT (n=68)
Stratified by age, type of medication, severity of depression, and presence of recurrence and/or relapse
Does pharmaceutical care via pharmacotherapy follow-up improve depressive symptoms in female patients diagnosed with depression?
Absolute Event Rate: 13.5% vs 2.5%
Pharmacotherapy follow-up by a pharmacist significantly reduces depressive and anxious symptoms in female patients with depression.
A 2013 study conducted an RCT in Depression (n=68). Pharmacotherapy follow-up (PF) according to the Dáder Method vs. Usual treatment (monthly visits without PF) was evaluated on Reduction in Beck Depression Inventory score. Pharmacotherapy follow-up significantly reduced depressive symptoms compared to usual care, with a median reduction in Beck Depression Inventory score of 13.5 points versus 2.5 points.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: